alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

30,580 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 51–75 of 131 studies in Vascular contributions · free to read (page 3 of 6) · 30,580 in the whole library · How the 0–100 score works

Download bibliography of these 131 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Other subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 16,054 studies have no institution on record and are not counted here.

What “Vascular contributions” covers

Vascular contributions — How blood vessel health, small-vessel disease and stroke risk contribute to dementia and cognitive decline.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Clinical and neuroimaging correlates of motoric cognitive risk syndrome in cerebral small vessel disease: a cross-sectional study

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Frontiers in Aging Neuroscience 2026-06-11

Among 225 patients (mean age 65.4 years, 54.2% male), MCR prevalence was 16.4%. 5 key findings →

Design: cross-sectional Participants: 225 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Tongxinluo capsule in the treatment of cerebral small vessel disease: protocol of a randomised, double-blind, placebo-controlled, multicentre clinical study (TOPS-CSVD)

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Stroke and Vascular Neurology 2025-09-10

The primary outcome of this clinical trial is the change in the Vascular Dementia Assessment Scale-cognitive subscale from baseline to 12 months. 3 key findings →

Participants: 1,052 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Cerebral small vessel disease: The impact of glymphopathy and sleep disorders

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Journal of Cerebral Blood Flow & Metabolism 2025-05-05

The glymphatic system, a vital brain perivascular network for waste clearance, hinges on the functionality of the aquaporin 4 (AQP4) water channel. 5 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Neurovascular Decoupling Is Associated With Lobar Intracerebral Hemorrhages and White Matter Hyperintensities

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Journal of the American Heart Association 2025-02-14

This raises the suggestion that a decreased neurovascular coupling in the disease process of AD is related to comorbid small vessel disease. 2 key findings →

Participants: 119 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Higher Burden of Cerebral Small Vessel Disease Is Associated With Risk of Incident Stroke in Community‐Dwelling Individuals

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Journal of the American Heart Association 2025-11-06

Among 1154 participants (46% men, mean age 70.9±8.7 years), 92 (8%) developed stroke over a median follow-up of 8.6 years (Q1-Q3: 5.1-12.5). 5 key findings →

Participants: 1,154 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Associations of early-onset coronary heart disease and genetic susceptibility with incident dementia and white matter hyperintensity: A prospective cohort study

✓ Peer-reviewed alzhub usefulness score 47 out of 100. The Journal of Prevention of Alzheimer s Disease 2025-01-23

=0.002). Early-onset CHD and genetic susceptibility are associated with a higher risk of incident dementia and a larger WMH volume. 2 key findings →

Design: cohort study Participants: 671 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

DCE-MRI reveals spatial pattern in heterogeneous blood-brain barrier leakage within white matter in cerebral small vessel disease

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Journal of Cerebral Blood Flow & Metabolism 2025-08-04

Cerebral small vessel disease (cSVD) is associated with vascular cognitive impairment, dementia, and stroke. 3 key findings →

Design: cross-sectional Participants: 59 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Unraveling Homocysteine's Role in Dementia: No Specific Association with Alzheimer's Disease, but a Connection to White Matter Hyperintensities

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Aging and Disease 2025-01-01

Hyperhomocysteinemia (HHcy) is an established risk factor for cognitive impairment. 2 key findings →

Design: cross-sectional Participants: 507 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Cerebral small vessel disease and effects of intensive versus standard blood pressure treatment on cardiovascular outcomes and adverse events

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Journal of Hypertension 2025-06-27

The mean age of the participants was 68 ± 9 years and 39% were female. 5 key findings →

Design: post-hoc analysis Participants: 759 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Elevated serum inflammasome adaptor protein ASC is associated with white matter hyperintensities in vascular cognitive impairment

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Brain Communications 2026-01-01

Alzheimer's disease (AD) and vascular dementia (VaD) exhibit distinct neuropathological hallmarks, with AD defined by cortical amyloid plaques and neurofibrillary tangles, while VaD arises primarily from cerebrovascular disease (CeVD). 4 key findings →

Participants: 531 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Pulse Pressure, White Matter Hyperintensities, and Cognition: Mediating Effects Across the Adult Lifespan

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Annals of Clinical and Translational Neurology 2025-05-25

Pulse pressure, but not mean arterial pressure, significantly mediated the relationship between age and white matter hyperintensity load. 5 key findings →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Plasma placental growth factor as a biomarker for subcortical ischemic vascular dementia and its cognitive correlation mediated by white matter hyperintensities

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Alzheimer s & Dementia 2025-07-01

The plasma PlGF level was significantly elevated in patients with SIVD compared with CUCs, and showed a high accuracy with an area under the curve of 0.893. 5 key findings →

Participants: 102 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Mapping the Association of Cerebral Small Vessel Disease, Gray Matter Integrity, and Cognitive Function

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Neurology 2025-10-17

= 0.026). Complementing previous research that focuses on CSVD and white matter changes, our study highlights abnormal gray matter integrity as a possible link between small vessel pathology and cognitive disorders. 1 key finding →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

White matter hyperintensity tissue property spatial variations as a function of cognitive status in Parkinson’s disease

✓ Peer-reviewed alzhub usefulness score 46 out of 100. NeuroImage 2025-04-23

• Patients with Parkinson's disease (PD) and cognitive impairment demonstrated a significantly greater burden of white matter hyperintensities (WMH), with the highest burden observed in those with PD dementia. 5 key findings →

Participants: 122 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

A more irregular shape of white matter hyperintensities is associated with cognitive decline over five years in community-dwelling older adults

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Neurobiology of Aging 2025-04-03

WMH shape is associated with long-term risk for dementia after 10 years in community-dwelling older adults. 2 key findings →

Participants: 2,493 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Polygenic risk for white matter hyperintensities is associated with early cerebrovascular events partly through hemodynamic measures in cognitively unimpaired middle-aged and older adults with low cardiovascular risk

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Frontiers in Neurology 2026-01-05

They are often found in middle-aged individuals and are associated with a greater risk of stroke and vascular dementia. 5 key findings →

Participants: 1,072 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Silent yet impaired: Hidden memory processing deficits in asymptomatic individuals with moderate‐to‐severe white matter hyperintensities

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Alzheimer s & Dementia 2026-01-01

Individuals with msWMH showed systematic deficits in face-memory processing across encoding, maintenance, and retrieval, accompanied by reduced theta power and synchronization, altered alpha power, and disrupted theta-gamma coupling. 5 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

The role of Tau, amyloid-β and neuroinflammation in the association between cognition and white matter hyperintensities in a southeast Asian cohort

✓ Peer-reviewed alzhub usefulness score 44 out of 100. The Journal of Prevention of Alzheimer s Disease 2025-08-05

WMH burden positively correlated to Neurofilament-Light (NfL) and pTau181. 5 key findings →

Design: cross-sectional Participants: 583 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

White Matter Hyperintensities in Behavioral Variant Frontotemporal Dementia and Semantic Variant Primary Progressive Aphasia

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Neurology Open Access 2026-01-23

hexanucleotide repeat expansions (HRE) and WMH in bvFTD patients. bvFTD and svPPA are associated with elevated WMH burden independent of CVRF. 3 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Retinal microvascular dysfunction in mild cognitive impairment: Associations with cerebral small vessel disease, plasma biomarkers, and cognitive decline

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Alzheimer s & Dementia 2026-02-01

MCI exhibited greater retinal tortuosity (p < 0.05) and sparser vasculature (p < 0.001), correlating with higher PSMD, WMH volumes, and adverse plasma biomarkers (all p < 0.05). 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Multi-Ancestry Transcriptome-Wide Association Studies of Cognitive Function, White Matter Hyperintensity, and Alzheimer’s Disease

✓ Peer-reviewed alzhub usefulness score 43 out of 100. International Journal of Molecular Sciences 2025-03-09

Genetic variants increase the risk of neurocognitive disorders in later life, including vascular dementia (VaD) and Alzheimer’s disease (AD), but the precise relationships between genetic risk factors and underlying disease etiologies are not well understood. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 30,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,580 records, built mostly from automated pulls of Europe PMC (64.7% of the library) and OpenAlex (16.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,037 records (3.4% of the library) are not peer-reviewed — 964 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events